EICHORPublic-registry site landscape for NCT07701486, “A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer”, a Pancreas Cancer, Metastatic study sponsored by Theriva Biologics SL. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07701486 (registry record) |
| Study title | A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer |
| Official title | A Phase IIa, Single-arm, Single-center, Open Label, Proof-of-concept Trial Evaluating Increased Frequency Dosing of VCN-01 (Zabilugene Almadenorepvec) in Combination With Nab-Paclitaxel/Gemcitabine (GnP) in Patients With Newly-Diagnosed Metastatic Pancreatic Cancer |
| Sponsor | Theriva Biologics SL |
| Condition(s) | Pancreas Cancer, Metastatic; Pancreas Cancer, Stage IV; Ductal Adenocarcinoma of the Pancreas |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 1 |
| Site countries | Spain |
At Hospital 12 de Octubre — one of the facilities listed on this trial — 10 other studies are actively recruiting Pancreas Cancer, Metastatic patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Patient-friendly overview of this study: eichor.com/study/NCT07701486.
Eichor generates a preliminary site-risk snapshot for NCT07701486 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
More from Theriva Biologics SL
← Eichor home · All tracked trials · Pancreas Cancer, Metastatic studies · Weekly briefs
